Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA
() -- Celltrion (KRX:068270) submitted an investigational new drug (IND) amendment for a global Phase 3 trial of CT-P51, the biosimilar of its cancer drug Keytruda, to the U.S. Food & Drug Administration, according to a Monday filing with the Korea Exchange. The randomized, double-blind, active-controlled clinical tria